Overview

Clinical Trial for Ovarian Cancer (OvaRex®)

Status:
Terminated

Trial end date:
2007-12-01

Target enrollment:

Participant gender:

Summary

This study will compare the time to disease relapse between OvaRex® MAb-B43.13-treated patients and placebo-treated patients. This study will also compare assessments of survival, quality of life, immune response and safety between active and placebo groups.

Phase:

Phase 3

Details

Lead Sponsor:

Unither Pharmaceuticals

Treatments:

Oregovomab